Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2026)
Protalix BioTherapeutics' quarterly Tax Provisions came in at $2.8 million in Q1 2026, up 2536.28% year-on-year from $104427.3 in Q1 2025, and up 387.26% quarter-over-quarter from $565000.0 in Q4 2025.
Protalix BioTherapeutics has reported Tax Provisions for 4 years, with the latest figure at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 2536.28% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 129.87% YoY), and the FY2025 full-year result was $656000.0, down 46.32% from the prior year.
- Tax Provisions for Q1 2026 stood at $2.8 million, up from $565000.0 in the prior quarter.
- The five-year high for Tax Provisions was $3.4 million in Q2 2023, with the low at -$175000.0 in Q3 2025.
- Average Tax Provisions over 4 years is $863846.2, with a median of $266000.0 recorded in 2025.
- Year-over-year, Tax Provisions plunged 170.77% in 2024 and surged 2536.28% in 2026.
- Tracing PLX's Tax Provisions over 4 years: stood at $2.7 million in 2023, then sank by 60.96% to $1.1 million in 2024, then slumped by 46.6% to $565000.0 in 2025, then jumped by 387.26% to $2.8 million in 2026.
- The last three Tax Provisions figures came in at $2.8 million (Q1 2026), $565000.0 (Q4 2025), and -$175000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.75 Mn |
| Dec 31, 2025 | 565,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Jun 30, 2025 | 266,000.00 |
| Mar 31, 2025 | -113,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 607,000.00 |
| Jun 30, 2024 | -69,000.00 |
| Mar 31, 2024 | -138,000.00 |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 133,000.00 |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 195,000.00 |